Fabry
Disease Market Size was valued at USD 2.1 billion in 2022 and is projected to
grow from USD 2.26 Billion in 2023 to USD 4.12 billion by 2032, exhibiting a
compound annual growth rate (CAGR) of 7.8% during the forecast period (2023 -
2032).
The
Fabry disease market witnesses dynamic growth, driven by
advancements in diagnosis, treatment, and rising awareness. Characterized by
alpha-galactosidase A enzyme deficiency, Fabry disease impacts multiple organs,
causing significant morbidity and mortality. Enzyme replacement therapies
(ERTs) like agalsidase alfa and beta, along with substrate reduction therapies
(SRTs), constitute primary treatments, targeting glycolipid accumulation.
Despite effective interventions, challenges persist, including high treatment
costs and limited accessibility in some regions. Biopharmaceutical companies
continue research to develop novel therapies, focusing on enhanced efficacy and
patient convenience. Increasing investment in precision medicine and gene
therapy offers promising avenues for the Fabry disease market's future
expansion and innovation.
Fabry
disease, also known as Anderson-Fabry disease, is a rare genetic disorder characterized
by the deficiency of an enzyme called alpha-galactosidase A (α-Gal A). This
enzyme deficiency leads to the accumulation of a type of fat called
globotriaosylceramide (Gb3) in various cells throughout the body. Fabry disease
affects multiple organs and systems, including the kidneys, heart, skin, and
nervous system.
The
Fabry disease market encompasses various aspects related to the diagnosis,
treatment, and management of this condition. With advancements in genetic
testing and molecular diagnostics, early detection of Fabry disease has become
more feasible, enabling timely interventions to mitigate its progression.
Treatment
options for Fabry disease primarily focus on enzyme replacement therapy (ERT),
which aims to replenish the deficient α-Gal A enzyme levels in the body.
Additionally, supportive therapies may be prescribed to manage symptoms and
improve patients' quality of life.
As
awareness about Fabry disease grows among healthcare professionals and the
general population, efforts to improve diagnostic techniques and therapeutic
interventions continue to expand. Pharmaceutical companies are investing in
research and development to innovate new treatment modalities and enhance
existing therapies for Fabry disease.
Overall,
the Fabry disease market is driven by advancements in medical science,
increasing awareness, and collaborative efforts among stakeholders to address
the unmet needs of patients affected by this rare genetic disorder. With
ongoing research and clinical developments, there is optimism for improved
outcomes and enhanced quality of life for individuals living with Fabry
disease.
Market
Segmentation:
The Global Fabry Disease Market
has been segmented into type, diagnosis & treatment and end user.
The market, on the basis of
type, has been segmented into type-1 and type-2. The type-2 Fabry disease holds
the major market share due to the high occurrence of type-2 Fabry disease i.e.
1 in 1,500 to 4000 males.
The market, by diagnosis &
treatment, has been segmented into diagnosis and treatment. The diagnosis
segment is further classified as blood test, urine test, thyroid test, lung
function test, and imaging. The imaging segment includes electrocardiogram
(EKG), echocardiogram, brain MRI, CT scan and others. The treatment segment is
further classified as enzyme replacement therapy, gene therapy, pharmaceutical
formulations containing agalsidase alfa, analgesics, anticonvulsants,
nonsteroidal anti-inflammatory drugs (NSAIDs), and others.
Regional
Analysis:
Geographically,
the Americas is expected to dominate the global market owing to the increasing
technological advancements and rising research and development activities.
Gastrointestinal manifestations such as abdominal pain, diarrhea and nausea are
significant burden in a patient with Fabry disease. So, for the advanced
treatment of these patients SmartPill testing procedure is developed to gain
additional understanding of Fabry disease manifestation via motility
abnormalities in order to improve symptom targeted therapy. This device is
currently under clinical trial and the sponsor of this study is Massachusetts
General Hospital.
Europe
is expected to hold the second largest market share. Nearly 2.2 in 10,000
people in the European Union (EU) are affected with Fabry disease and Fabrazyme
(agalsidase beta), Galafold (migalastat) and Replagal (agalsidase alfa) are the
three authorized drugs used for the treatment of Fabry disease.
Key
Players:
The
global Fabry disease companies are Amgen Inc., Amicus Therapeutics, Inc.,
AVROBIO, Inc., Idorsia Pharmaceuticals Ltd, Protalix, Bristol-Myers Squibb
Company, GlaxoSmithKline, iBio, Inc., Neuraltus Pharmaceuticals, Inc., Novartis
AG, Pfizer Inc., Sanofi, Shire, Takeda Pharmaceutical Company Limited, Teva
Pharmaceutical Industries Ltd and others.
Related Reports:
Live Cell Imaging Market Research Report – Forecast to 2032
Lab-on-a-Chip Device Market Research Report – Forecast to 2032
U.S., India and Europe CBCT Dental Imaging
North America Clinical Laboratory Test
Middle East and Africa Urinary Catheters
For More Information, Please Visit @ Market Research Future
Comments
Post a Comment